- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00006341
Dentures and Dental Implants in Treating Patients Undergoing Surgery for Mouth Cancer
Efficacy of Implant-Supported Maxillofacial Prostheses
RATIONALE: The use of dentures and dental implants may help maintain chewing and speaking ability following surgery to remove tumors in the mouth.
PURPOSE: Phase II trial to study the effectiveness of dentures and dental implants in maintaining the ability to chew and speak in patients undergoing surgery for mouth cancer.
Panoramica dello studio
Descrizione dettagliata
OBJECTIVES:
- Determine whether conventional or implant supported dental prostheses and current surgical reconstructive procedures restore oral function and quality of life to pre-cancer surgery levels in patients with early oral cancer.
OUTLINE: Patients complete a series of objective and subjective functional tests, questionnaires, and baseline examinations. Within 1-5 days, patients undergo the composite resection, including reconstructive surgery for the mandibulectomy group. Patients in the maxillectomy group receive an immediate maxillary surgical obturator. Approximately 6 weeks after ablative surgery, some patients receive radiotherapy for 5-7 weeks.
Patients receive 2-4 implants at 12-16 weeks after completion of radiotherapy or 8-16 weeks after ablative surgery. Patients then receive conventional dentures at 4-22 weeks after implant surgery. Implants are exposed during 27-48 weeks after placement and abutments connected for fabricating dental prostheses. Approximately 8 weeks are needed to fabricate the implant supported prosthesis.
Patients complete quality of life and other questionnaires prior to and at 8-21 weeks after surgery, 16 weeks after conventional denture insertion, and then 16 weeks after implant supported prosthesis insertion.
Patients are followed every 6 months for at least 3 years.
PROJECTED ACCRUAL: A total of 62 patients (22 requiring maxillectomy and 40 requiring mandibulectomy) will be accrued for this study within 42 months.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
California
-
Los Angeles, California, Stati Uniti, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
DISEASE CHARACTERISTICS:
Diagnosis of early oral cancer lesions requiring one of the following:
- Partial or total unilateral maxillectomy OR
- Partial lateral mandibulectomy with or without partial glossectomy
- Edentulous or edentulous in the maxillary arch prior to or after ablative surgery (maxillectomy group)
- Partial mandibulectomy leaving the condyles intact bilaterally (mandibulectomy group)
- Must have sufficient bone in the selected implant sites to accommodate 2-4 implants of at least 10 mm in length
- No temporomandibular dysfunction and/or functionally restrictive opening
- No requirement for total glossectomy, reconstructive maxillary surgery, or maxillary sinus lift
- No requirement for radiotherapy after mandibular reconstructive surgery
PATIENT CHARACTERISTICS:
Age:
- 35 to 80
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- No oral discomfort that would preclude study
- No complications after ablative or reconstructive surgery that would preclude dental rehabilitation with implants
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Not specified
Endocrine therapy:
- Not specified
Radiotherapy:
- See Disease Characteristics
- No prior or concurrent radiotherapy of greater than 5,500 cGY to potential implant site
Surgery:
- See Disease Characteristics
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Implant
A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled.
The mandibular defects will be reconstructed with fibula free flap surgery.
Following a healing period, implants will be placed and permitted to heal unloaded for six months.
Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded.
A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
|
A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled.
The mandibular defects will be reconstructed with fibula free flap surgery.
Following a healing period, implants will be placed and permitted to heal unloaded for six months.
Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded.
A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
|
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Neal R. Garrett, PhD, Jonsson Comprehensive Cancer Center
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CDR0000066588
- UCLA-HSPC-940205413
- UCLA-DEN-1R01DE11255
- UCLA-HSPC-940205411
- NCI-V00-1606
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro testa e collo
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
Prove cliniche su Implant
-
Apreo Health, Inc.ReclutamentoEnfisema o BPCORegno Unito, Austria, Olanda
-
Apreo Health, Inc.ReclutamentoEnfisema o BPCOAustralia
-
Zimmer BiometRitiratoMalattia degenerativa del discoStati Uniti
-
Massachusetts General HospitalSconosciutoCancro al seno | Chirurgia | Articolo chirurgico, trattenuto
-
The Royal College of Surgeons of EdinburghReclutamentoPerdita ossea alveolareEgitto, Germania
-
Farhan KarimDePuy SynthesReclutamentoMalattia degenerativa del disco | Stenosi spinale lombare | Spondilolistesi lombare | Stenosi foraminaleStati Uniti
-
Guy's and St Thomas' NHS Foundation TrustSconosciuto
-
LifeCellTerminatoMastectomia e ricostruzione mammariaFrancia, Germania, Regno Unito
-
Advanced BionicsCompletatoMalattie otorinolaringoiatriche | Malattie dell'orecchio | Perdita dell'udito | Disturbi dell'uditoStati Uniti
-
Ideal Implant IncorporatedCompletato